Stage III endometrial carcinoma. A review of 90 cases.
The authors present a retrospective review of 90 cases of Stage III endometrial carcinoma seen over a 10-year period at the Princess Margaret Hospital, Toronto. Overall 5-year survival was 45.5% and disease-free survival was 36.0%. Prognostic factors identified within Stage III were tumor grade, geographic distribution of disease, the presence of symptoms other than vaginal bleeding or discharge, and completeness of surgery. Isolated involvement of the ovary or fallopian tube emerges as a distinct syndrome with a good prognosis (5-year survival of 82.3%). Surgery is the treatment of choice for operable cases, but 13 of 36 patients with inoperable disease who completed radical radiotherapy were alive and free of disease at 5 years.
W J
WJ
Mackillop
J F
JF
Pringle
D000230:Adenocarcinoma / Q000473:pathology* / Q000556:secondary; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000473:pathology* / Q000556:secondary; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000627:therapeutic use; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010166:Palliative Care; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D013997:Time Factors; D014594:Uterine Neoplasms / Q000401:mortality / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery
D008525:Medroxyprogesterone